Keyphrases
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Type 2 Diabetic Patients
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
Hemoglobin A1c (HbA1c)
44%
Placebo
33%
Serious Adverse Events
33%
Lipids
22%
Beneficial Effects
22%
Oral Antidiabetic Drugs
22%
Blood Pressure
22%
Randomized Controlled Trial
22%
Creatinine
11%
Ketoacidosis
11%
Serum Creatinine
11%
Adverse Events
11%
Diabetes Management
11%
Severe Hypoglycemia
11%
Urinary Tract Infection
11%
Liver Function Tests
11%
Therapeutic Agents
11%
Alanine Aminotransferase
11%
Non-serious
11%
Large Reduction
11%
A1c Levels
11%
Sulfonylurea
11%
Reproductive Tract Infections
11%
Fasting Plasma Glucose
11%
Dipeptidyl peptidase-4 (DPP-4)
11%
Confidence Interval
11%
Drug Class
11%
Heart Rate
11%
Glycated Hemoglobin A1c
11%
Publication Bias
11%
Manual Search
11%
Metformin
11%
Number of Patients
11%
Medicine and Dentistry
Meta-Analysis
100%
Patient with Type 2 Diabetes
100%
Systematic Review
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Hemoglobin A1c
55%
Adverse Event
44%
Placebo
33%
Oral Antidiabetic Agent
22%
Randomized Controlled Trial
22%
Creatinine
22%
Blood Pressure
22%
Ketoacidosis
11%
Alanine Aminotransferase
11%
Hypoglycemia
11%
Sulfonylurea
11%
Urinary Tract Infection
11%
Dipeptidyl Peptidase-4 Inhibitor
11%
Diabetes
11%
Infection
11%
Glycon
11%
Body Weight
11%
Genital Tract Infection
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Hemoglobin A1c
55%
Adverse Event
44%
Placebo
33%
Randomized Controlled Trial
22%
Oral Antidiabetic Agent
22%
Creatinine
22%
Hypoglycemia
11%
Ketoacidosis
11%
Alanine Aminotransferase
11%
Sulfonylurea
11%
Genital Tract Infection
11%
Dipeptidyl Peptidase IV Inhibitor
11%
Infection
11%
Metformin
11%
Urinary Tract Infection
11%